Terconazole


w14



General information:


Withdrawn ID: w14
Canonical SMILES:
Standard InChI:
Standard InChIKey:
ATC class(es): G01AG02
Molecular Formula: C26H31Cl2N5O3
Molweight: 532.47



Withdrawal information:


Withdrawn due to drug safety reasons:Yes
First approved: 1987
First withdrawn: 1991
Last withdrawn: 1991
Reference: https://www.ncbi.nlm.nih.gov/pubmed/26109960



Side-effects:

Total reported cases (submitted by medical professionals) with Terconazole as primary suspect: 32


Reported final outcomes:
Congenital anomaly: 3
Death: 1


Reported side-effects:

Side-effect Case number
DRUG INEFFECTIVE6
Drug dose omission5
INFLUENZA LIKE ILLNESS4
Hypersensitivity3
VULVOVAGINAL DISCOMFORT3
PAIN3
CHILLS3
VULVOVAGINAL PAIN2
Expired product administered2
DRUG EXPOSURE DURING PREGNANCY2
INTRA-UTERINE DEATH2
PRODUCT PACKAGING ISSUE2
APPLICATION SITE PAIN2
APPLICATION SITE IRRITATION2
APPLICATION SITE BURN2
URINARY TRACT INFECTION2
Adverse event2
Discomfort1
ABDOMINAL PAIN1
HYPERHIDROSIS1
HEPATIC PAIN1
HEADACHE1
WRONG DRUG ADMINISTERED1
DYSPNOEA1
Abdominal pain upper1
DRUG HYPERSENSITIVITY1
ABNORMAL FAECES1
ANTICHOLINERGIC SYNDROME1
DRUG DISPENSING ERROR1
APPLICATION SITE PRURITUS1
Device issue1
Device allergy1
Dermatitis contact1
COSTOCHONDRITIS1
Circumstance or information capable of leading to medication error1
Chemical burn1
Basal cell carcinoma1
Back pain1
ARTHRALGIA1
Product container issue1
Vaginal infection1
VAGINAL HAEMORRHAGE1
Vaginal discharge1
Underdose1
SKIN IRRITATION1
RASH GENERALISED1
RASH1
PYREXIA1
PRURITUS1
PRODUCT SUBSTITUTION ISSUE1
Product storage error1
Product quality issue1
Product packaging quantity issue1
Product design issue1
HYPERVENTILATION1
PREMATURE LABOUR1
PREMATURE BABY1
PHARMACEUTICAL PRODUCT COMPLAINT1
Pelvic pain1
MIOSIS1
MEDICATION ERROR1
INFLUENZA1
Inflammatory marker increased1
INCORRECT ROUTE OF DRUG ADMINISTRATION1
INCORRECT DOSE ADMINISTERED1
Incorrect dosage administered1
IMPATIENCE1
HYPOTENSION1
HYPOPLASTIC LEFT HEART SYNDROME1





Filtered ChEMBL targets:

Target UniProtKB ID Activity in nm Target Name Target gene
Q16850 3000 Lanosterol 14-alpha demethylase CP51A_HUMAN



Toxicity information:

Toxicity class: 5
Toxicity type: dermatological
LD50: 4000 mg/kg



External links:

ChEBML: CHEMBL1306
DrugBank: DB00251